GLP-1 Receptor Agonists in Type 2 Diabetes Management

Mechanisms of Anti-Inflammatory Action

GLP-1 receptor agonists improve endothelial function through multiple anti-inflammatory pathways, including effects on arterial walls and the autonomic nervous system, in patients with type 2 diabetes 1, 2, 3
These agents reduce atherosclerotic plaque formation through direct anti-inflammatory actions on vascular tissues, contributing to their cardiovascular benefits 1, 2
GLP-1 receptor agonists reduce myocardial ischemia injury through improved substrate utilization and anti-inflammatory effects, protecting against cardiovascular events 2
They lower markers of inflammation, including C-reactive protein and interleukin-6, as demonstrated in cardiovascular outcome trials, which is associated with reduced cardiovascular risk 1, 2
GLP-1 receptor agonists favorably modify lipid metabolism, reducing triglycerides and increasing HDL cholesterol, which contributes to their anti-inflammatory and cardiovascular benefits 2

The LEADER trial showed that Liraglutide reduced the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, or stroke by 13% compared to placebo in patients with type 2 diabetes at high cardiovascular risk 2
The SUSTAIN-6 trial demonstrated that Semaglutide reduced the primary cardiovascular outcome by 26% compared to placebo in patients with type 2 diabetes 2
The SELECT trial found that Semaglutide reduced the primary cardiovascular endpoint by 20% compared to placebo in non-diabetic patients with pre-existing cardiovascular disease and BMI > 27 2

The European Heart Society recommends GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and chronic coronary syndrome to reduce cardiovascular events (Class I, Level A recommendation) 4, 5
GLP-1 receptor agonists reduce albuminuria and slow eGFR decline, partly through anti-inflammatory mechanisms affecting the kidney, which is beneficial for patients with chronic kidney disease 6
Meta-analyses of cardiovascular outcome trials show that GLP-1 receptor agonists significantly reduce the risk of major adverse cardiovascular events, with greater benefit in patients with established cardiovascular disease 6

The European Heart Society recommends GLP-1 receptor agonists with proven cardiovascular benefit as first-line treatment for patients with type 2 diabetes and chronic coronary syndrome, independent of baseline HbA1c (Class I, Level A recommendation) 4, 5
Semaglutide should be considered in overweight or obese patients with chronic coronary syndrome without diabetes to reduce cardiovascular mortality, MI, or stroke (Class IIa, Level B recommendation) 4, 5
GLP-1 receptor agonists with proven cardiovascular benefit are recommended for patients with type 2 diabetes and CKD who do not meet individualized glycemic targets with metformin and/or SGLT2i 6

Gastrointestinal side effects, such as nausea, vomiting, and diarrhea, are common but usually tolerable with dose titration and typically abate over several weeks to months 1, 2
The American College of Cardiology recommends starting at the lowest dose and titrating slowly to mitigate gastrointestinal side effects, and considering medication adjustments, such as reducing total daily insulin dose by up to 20% and discontinuing DPP-4 inhibitors when starting therapy 7
Patients should monitor glucose more closely during the first 4 weeks of therapy, especially if on insulin or sulfonylureas 7

For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, GLP-1 receptor agonists provide the greatest evidence for MACE benefit through anti-inflammatory mechanisms, according to the American Diabetes Association 8, 9
The American College of Cardiology recommends considering GLP-1 receptor agonists in high-risk patients aged ≥55 years with coronary, carotid, or lower extremity artery stenosis >50%, left ventricular hypertrophy, eGFR <60 mL/min/1.73m², or albuminuria 8, 9
The decision to treat with GLP-1 receptor agonists to reduce MACE, heart failure hospitalization, cardiovascular death, or CKD progression should be made independently of baseline HbA1c or individualized HbA1c target, as suggested by the American Diabetes Association 8, 9

The American College of Cardiology recommends starting at the lowest dose and titrating slowly to mitigate gastrointestinal side effects while achieving anti-inflammatory benefits 10
The American College of Cardiology suggests discontinuing DPP-4 inhibitors before starting GLP-1 receptor agonist therapy, and reducing sulfonylurea dose by 50% or basal insulin dose by 20% when starting therapy if HbA1c is well-controlled at baseline or there is a history of frequent hypoglycemic events 10
The American College of Cardiology advises instructing patients to monitor glucose more closely during the first 4 weeks of therapy 10

The American Diabetes Association recommends not withholding GLP-1 receptor agonists in patients with established cardiovascular disease based solely on glycemic control status—the anti-inflammatory and cardiovascular benefits are independent of glucose-lowering effects 8, 9